At the chronic phase of SGLT2 inhibitor therapy, the reduced but preserved ePV will avoid the loss of tissue/organ perfusion, and the continued eEV removal will regulate fluid volume imbalance and mitigate congestion, potentially supporting, at least in part, the aforementioned clinical benefits of SGLT2 inhibitors, particularly for HF. Here, SLC5A2 is linked to hydrops fetalis.